Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.
Ticlopidine (Ticlodone: CAS 55142-85-3) is able to develop a positive effect on claudication in patients affected by peripheral atherosclerotic disease (PAD). It is also known that ticlopidine decreases fibrinogen levels in plasma. 15 PAD patients treated with ticlopidine for 3 months were studied, evaluating the drug's effect both on maximum walking distance and on fibrinogen. Plasma fibrinogen as coagulable protein, fibrinogen antigen (Partigen method), 125I-fibrinogen survival, euglobulin lysis time and plasminogen were determined with the aim of clarifying if the decrease of plasma fibrinogen induced by ticlopidine is due to an increased destruction of a decreased production of the molecule. The normal levels of all tests before and after therapy both in ticlopidine treated patients and in the control group (acetylsalicylic acid + dipyridamol) indicate that the two hypotheses are not true. It is proposed that ticlopidine developing the known effect in decreasing the binding of fibrinogen to platelets induces a decrease only of activated fibrinogen.
Randi
M L
ML
Institute of Medical Semeiotics, University of Padua Medical School, Italy.
Mares
M
M
Fabris
F
F
Tison
T
T
Barbone
E
E
Girolami
A
A
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001760:Bleeding Time; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D013988:Ticlopidine / Q000627:therapeutic use*; D016138:Walking
D005340:Fibrinogen; D013988:Ticlopidine